|Dr. Paul A. Friedman M.D.||Chairman & CEO||1.07M||N/A||1943|
|Dr. Rebecca A. Taub M.D.||Founder, Chief Medical Officer, Pres of R&D and Director||830.06k||N/A||1952|
|Mr. Brian J. Lynch J.D.||Gen. Counsel||698.05k||N/A||1962|
|Mr. Remy Sukhija||Chief Commercial Officer||714.9k||N/A||1973|
|Mr. Alex G. Howarth||Chief Financial Officer||N/A||N/A||1969|
|Dr. Kianoush Motesharei Ph.d.||Sr. VP of Bus. & Corp. Devel.||N/A||N/A||1970|
|Mr. Edward Chiang||Sr. VP of Clinical & Technical Operations||N/A||N/A||N/A|
|Mr. Thomas W. Hare||Sr. VP of Clinical Management||N/A||N/A||N/A|
|Dr. Robert E. Waltermire Ph.D.||Chief Pharmaceutical Devel. Officer||N/A||N/A||N/A|
|Dr. Stephen Dodge M.B.A., Pharm.D.||Sr. VP of Global Medical Affairs||N/A||N/A||N/A|
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 7.